Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity

By Shannon Lee, Jens Rauch, Walter Kolch. International Journal of Molecular Sciences, 2020

713 citations recorded by the source corpus.

Mitogen-activated protein kinase (MAPK) pathways represent ubiquitous signal transduction pathways that regulate all aspects of life and are frequently altered in disease. Here, we focus on the role of MAPK pathways in modulating drug sensitivity and resistance in cancer. We briefly discuss new findings in the extracellular signaling-regulated kinase (ERK) pathway, but mainly focus on the mechanisms how stress activated MAPK pathways, such as p38 MAPK and the Jun N-terminal kinases (JNK), impact the response of cancer cells to chemotherapies and targeted therapies. In this context, we also discuss the role of metabolic and epigenetic aberrations and new therapeutic opportunities arising from these changes.

Subfields: Molecular Biology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/f71e8b8cdf1f77882dca426e1a4eeafc0b86f926

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Qingxiang Zeng
2. Junjiang Liu
3. Jin Yang
4. J. Mu
5. Shuzhi Deng
6. Fanglong Wu
7. Ye Wang
8. Hongmei Zhou

Citations in the corpus

• Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer (2021, background): “Therefore, the MAPK pathway is divided into mitogen- and stress-activated MAPK pathways, with classical representatives being ERK as the mitogen-responsive MAPKs and JNK and p38 as the stress-responsive MAPKs.(156,157) Once the phosphorylation of ERK1/2, JNK1/2/3, or p38 is induced by an upstream ca”